BIOMARKER:

NRAS G12D

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

NRAS G12D	Melanoma	NRAS G12D	Melanoma	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3
NRAS G12D	Chronic Myelomonocytic Leukemia	NRAS G12D	Chronic Myelomonocytic Leukemia	trametinib Resistant: C4 – Case Studies trametinib Resistant : C4	trametinib Resistant: C4 – Case Studies trametinib Resistant : C4
NRAS G12D	Non Small Cell Lung Cancer	NRAS G12D	Non Small Cell Lung Cancer	bevacizumab + atezolizumab Sensitive: C4 – Case Studies bevacizumab + atezolizumab Sensitive : C4	bevacizumab + atezolizumab Sensitive: C4 – Case Studies bevacizumab + atezolizumab Sensitive : C4
NRAS G12D	Prostate Cancer	NRAS G12D	Prostate Cancer	BAY 1125976 Sensitive: D – Preclinical BAY 1125976 Sensitive : D	BAY 1125976 Sensitive: D – Preclinical BAY 1125976 Sensitive : D
NRAS G12D	Acute Lymphocytic Leukemia	NRAS G12D	Acute Lymphocytic Leukemia	U0126 Sensitive: D – Preclinical U0126 Sensitive : D	U0126 Sensitive: D – Preclinical U0126 Sensitive : D
NRAS G12D	Acute Myelogenous Leukemia	NRAS G12D	Acute Myelogenous Leukemia	PD98059 Sensitive: D – Preclinical PD98059 Sensitive : D	PD98059 Sensitive: D – Preclinical PD98059 Sensitive : D
NRAS G12D	Chronic Myelomonocytic Leukemia	NRAS G12D	Chronic Myelomonocytic Leukemia	selumetinib Resistant: D – Preclinical selumetinib Resistant : D	selumetinib Resistant: D – Preclinical selumetinib Resistant : D